指南与共识血栓与止血

DOACs与LMWHs在住院内科患者中的比较:系统综述与荟萃分析(为2018 ASH指南提供依据)

DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines.
指南 / 共识 · Blood Adv · 2020-01-01

该系统综述与荟萃分析纳入3项低偏倚风险的随机试验,比较住院急性内科疾病患者使用DOACs与其他药物预防静脉血栓栓塞的效果。结果显示DOACs与LMWHs相比未降低肺栓塞或有症状深静脉血栓风险,但大出血风险略有增加;先前报告的DOACs获益主要基于无症状DVT的减少,仅考虑有症状事件时并不明显。

要点

  • DOACs不降低住院内科患者肺栓塞或有症状DVT风险。
  • DOACs较LMWHs略微增加大出血风险。
  • DOACs的获益主要来自无症状DVT减少,有症状事件无差异。

核心结论

  • 住院内科患者使用DOACs较LMWHs略微增加大出血风险,且无明显获益。

研究设计与样本

  • 系统综述与荟萃分析,纳入3项低偏倚风险的随机试验,患者为因急性内科疾病住院者。
  • 分析两个时间点:短期治疗阶段结束(两药给药相同时间)和延长预防阶段结束(延长DOACs vs 较短疗程LMWHs)。

主要发现

  • DOACs与LMWHs相比未降低肺栓塞或有症状DVT风险。
  • DOACs大出血风险略有增加。
  • 先前报告的DOACs获益主要基于无症状DVT减少,仅考虑有症状事件时不明显。

临床怎么用

  • 住院内科患者预防VTE时,DOACs较LMWHs无净获益且大出血风险略增,决策需权衡出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a relatively frequent complication in hospitalized patients, especially in those with risk factors. The benefit of using direct oral anticoagulants (DOACs) for prevention is controversial. This systematic review was performed as part of the American Society of Hematology (ASH) guidelines on VTE, developed in partnership with McMaster University. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Epistemonikos were used as data sources from date of inception to November 2019. We included randomized trials in patients hospitalized for an acute medical disease, evaluating any DOACs vs other pharmacological prophylaxis, and included 3 trials with low risk of bias. We analyzed the effects of DOACs vs low-molecular-weight heparins (LMWHs) at 2 different time points: at the end of the short-term treatment phase (both drugs given for the same period of time) and at the end of the extended prophylaxis period (extended DOACs vs a shorter course of LMWHs). We observed that the use of DOACs did not reduce the risk of pulmonary embolism or symptomatic deep venous thrombosis (DVT) in comparison with LMWHs. However, the risk of major bleeding was slightly increased. Additionally, we observed that the benefit of DOACs previously reported was largely based on the reduction of asymptomatic DVT and was not apparent when only symptomatic events were considered. The use of DOACs in hospitalized medical patients slightly increases the risk of major bleeding with no appreciable benefit over LMWHs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Neumann I, Izcovich A, Zhang Y, et al. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv. 2020. PMID: 32289163. doi:10.1182/bloodadvances.2019000840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。